摘要
特发性膜性肾病(IMN)是由抗体介导的一种肾脏特异性疾病,经皮肾穿刺活检术是确诊IMN的金标准,目前认为M型磷脂酶A2受体(PLA2R)是IMN患者足细胞上的特异性靶抗原,血清中可检测出相应的抗体,这一发现彻底改变了既往膜性肾病(MN)的诊断和治疗方法。本综述将从血清抗磷脂酶A2受体抗体(PLA2R-Ab)对IMN的诊断、治疗及预后的临床意义方面进行阐述,并探讨目前尚未解决的问题。
Idiopathic membranous nephropathy(IMN)is a kind of kidney-specific disease mediated by antibodies.Percutaneous renal biopsy is the gold standard for the diagnosis of IMN.At present,it is considered that M-type phospholipase A2 receptor(PLA2R)is a specific target antigen on podocytes of patients with IMN,and the corresponding antibodies can be detected in serum.This discovery has completely changed the diagnosis and treatment methods of previous membranous nephropathy(MN).This review will expound the clinical significance of serum anti-phospholipase A2 receptor antibody(PLA2R-Ab)in the diagnosis,treatment and prognosis of IMN,and discuss the unsolved problems at present.
作者
张莹莹
郭彦聪
ZHANG Yingying;GUO Yancong
出处
《中国医学创新》
CAS
2023年第11期173-178,共6页
Medical Innovation of China
